AMG-517

AMG-517 is a drug which acts as a potent and selective blocker of the TRPV1 ion channel.^[1][2] It was developed as a potential treatment for chronic pain, but while it was an effective analgesic in animal studies it was dropped from human clinical trials at Phase I due to producing hyperthermia as a side effect, as well as poor water solubility. It is still used in scientific research into the function of the TRPV1 channel and its role in pain and inflammation, and has been used as a template for the design of several newer analogues which have improved properties.^{[3][4][5][6][7]}

AMG-517

Identifiers
IUPAC name N-(4-{6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}oxy-1,3-benzothiazol-2-yl)acetamide
CAS Number	659730-32-2
PubChem CID	16007367
ChemSpider	10609411
UNII	172V4FBZ75
ChEMBL	ChEMBL229430
CompTox Dashboard (EPA)	DTXSID90216178
Chemical and physical data
Formula	C20H13F3N4O2S
Molar mass	430.41 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)NC1=NC2=C(C=CC=C2S1)OC3=NC=NC(=C3)C4=CC=C(C=C4)C(F)(F)F
InChI InChI=1S/C20H13F3N4O2S/c1-11(28)26-19-27-18-15(3-2-4-16(18)30-19)29-17-9-14(24-10-25-17)12-5-7-13(8-6-12)20(21,22)23/h2-10H,1H3,(H,26,27,28) Key:YUTIXVXZQIQWGY-UHFFFAOYSA-N

See also

• AMG-9810
• SB-705498
• Discovery and development of TRPV1 antagonists